首页 › 基金 › FARALLON CAPITAL MANAGEMENT, L.L.C. › KLRA
FARALLON CAPITAL MANAGEMENT, L.L.C. 对 KLRA 的持仓历史
KAILERA THERAPEUTICS INC · 医疗保健
FARALLON CAPITAL MANAGEMENT, L.L.C. 在 Q2 2026 的 13F 申报中披露持有 KLRA(KAILERA THERAPEUTICS INC)1,100,000 股,市值约 US$24.2M,约占其申报组合的 0.11%,在其申报持仓中市值排名第 48 位。 FARALLON CAPITAL MANAGEMENT, L.L.C. 于 Q2 2026 首次申报该持仓。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
FARALLON CAPITAL MANAGEMENT, L.L.C. 对 KLRA 的持仓演变
FARALLON CAPITAL MANAGEMENT, L.L.C. 于 Q2 2026 首次披露 KLRA 持仓:1,100,000 股(约 US$24.2M)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 1.10M | $24.23M | 新进 |
关于 KLRA 与 13F 数据
KLRA(KAILERA THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 110 只申报持有 KLRA,申报仓位最大的包括:BAIN CAPITAL INVESTORS LLC (US$578.4M), Bain Capital Life Sciences Investors, LLC (US$497.5M), RTW INVESTMENTS, LP (US$237.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 KLRA 的基金
- BAIN CAPITAL INVESTORS LLC 26.26M 股 · $578.41M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 22.58M 股 · $497.51M · Q2 2026
- RTW INVESTMENTS, LP 10.78M 股 · $237.41M · Q2 2026
- Atlas Venture Life Science Advisors, LLC 5.17M 股 · $113.92M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.46M 股 · $54.09M · Q2 2026
- Siren, L.L.C. 2.21M 股 · $48.78M · Q2 2026
- 法拉龙资本管理 1.10M 股 · $24.23M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.10M 股 · $24.23M · Q2 2026
- Trails Edge Capital Partners, LP 984.79K 股 · $21.69M · Q2 2026
- Cormorant Asset Management, LP 550.00K 股 · $12.12M · Q2 2026
- Catalio Capital Management, LP 468.75K 股 · $10.33M · Q2 2026
- a16z Capital Management, L.L.C. 140.00K 股 · $3.08M · Q2 2026
更多关于 FARALLON CAPITAL MANAGEMENT, L.L.C.
常见问题
How long has FARALLON CAPITAL MANAGEMENT, L.L.C. held KLRA?
FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed KLRA holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is FARALLON CAPITAL MANAGEMENT, L.L.C.'s current position in KLRA?
As of Q2 2026, FARALLON CAPITAL MANAGEMENT, L.L.C. holds 1.10M shares of KLRA (KAILERA THERAPEUTICS INC), valued at $24.23M, representing 0.11% of its reported portfolio and ranking #48.
Has FARALLON CAPITAL MANAGEMENT, L.L.C. been buying or selling KLRA?
In the latest 13F filing (Q2 2026), FARALLON CAPITAL MANAGEMENT, L.L.C. newly opened its position in KLRA.
Which other funds hold KLRA?
Other major institutional holders of KLRA include BAIN CAPITAL INVESTORS LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, among 110 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.